Want to join the conversation?
$JNJ's Janssen Biotech unit announced that the US FDA has approved STELARA (ustekinumab) for the treatment of moderately to severely active Crohn's disease in adults who have failed or were intolerant to treatment with immunomodulators or corticosteroids. Crohn's disease is an inflammatory disease which affects the gastrointestinal tract.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.
$RAI has received a $47 billion take over offer from British tobacco giant British American Tobacco! This is huge!
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.